Innovent Biologics's Weight-Loss Drug Could Start to Generate Revenue This Year -- Market Talk

Dow Jones

Jun 30

0947 GMT - Innovent Biologics's newly approved weight-loss drug could begin to bring in revenue in 2H, Morningstar analyst Yurou Zheng says in a research note. Innovent secured approval last week in China for its weight-loss drug mazdutide. The analyst thinks the near-term challenge for mazdutide, or weight-loss drugs in general, is potential price competition. Users will likely pivot to cheaper options if the efficacy profiles are similar or even slightly less superior, the analyst says. "Over the long term, a bigger challenge for the industry would be coming up with the next generation weight loss drug, especially for orally administered ones with an emphasis on the small molecule modality for greater effect," she adds.(sherry.qin@wsj.com)

(END) Dow Jones Newswires

June 30, 2025 05:47 ET (09:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2547062013"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547062013\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547062013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547062013","market":"us","top_or_hot":-1,"title":"Innovent Biologics's Weight-Loss Drug Could Start to Generate Revenue This Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0947 GMT - Innovent Biologics's newly approved weight-loss drug could begin to bring in revenue in 2H, Morningstar analyst Yurou Zheng says in a research note. Innovent secured approval last week in China for its weight-loss drug mazdutide. The analyst thinks the near-term challenge for mazdutide, or weight-loss drugs in general, is potential price competition. Users will likely pivot to cheaper options if the efficacy profiles are similar or even slightly less superior, the analyst says. \"Over the long term, a bigger challenge for the industry would be coming up with the next generation weight loss drug, especially for orally administered ones with an emphasis on the small molecule modality for greater effect,\" she adds.(sherry.qin@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2025 05:47 ET (09:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics's Weight-Loss Drug Could Start to Generate Revenue This Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics's Weight-Loss Drug Could Start to Generate Revenue This Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-30 17:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0947 GMT - Innovent Biologics's newly approved weight-loss drug could begin to bring in revenue in 2H, Morningstar analyst Yurou Zheng says in a research note. Innovent secured approval last week in China for its weight-loss drug mazdutide. The analyst thinks the near-term challenge for mazdutide, or weight-loss drugs in general, is potential price competition. Users will likely pivot to cheaper options if the efficacy profiles are similar or even slightly less superior, the analyst says. \"Over the long term, a bigger challenge for the industry would be coming up with the next generation weight loss drug, especially for orally administered ones with an emphasis on the small molecule modality for greater effect,\" she adds.(sherry.qin@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2025 05:47 ET (09:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2547062013","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547062013","pubTimestamp":1751276820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0947 GMT - Innovent Biologics's newly approved weight-loss drug could begin to bring in revenue in 2H, Morningstar analyst Yurou Zheng says in a research note. Innovent secured approval last week in China for its weight-loss drug mazdutide. The analyst thinks the near-term challenge for mazdutide, or weight-loss drugs in general, is potential price competition. Users will likely pivot to cheaper options if the efficacy profiles are similar or even slightly less superior, the analyst says. \"Over the long term, a bigger challenge for the industry would be coming up with the next generation weight loss drug, especially for orally administered ones with an emphasis on the small molecule modality for greater effect,\" she adds.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"信达生物的减肥药今年可能开始产生收入——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9},"content_text":"0947 GMT - Innovent Biologics's newly approved weight-loss drug could begin to bring in revenue in 2H, Morningstar analyst Yurou Zheng says in a research note. Innovent secured approval last week in China for its weight-loss drug mazdutide. The analyst thinks the near-term challenge for mazdutide, or weight-loss drugs in general, is potential price competition. Users will likely pivot to cheaper options if the efficacy profiles are similar or even slightly less superior, the analyst says. \"Over the long term, a bigger challenge for the industry would be coming up with the next generation weight loss drug, especially for orally administered ones with an emphasis on the small molecule modality for greater effect,\" she adds.(sherry.qin@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 30, 2025 05:47 ET (09:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}